A Safety Signal Too Serious to Ignore
French pharmaceutical company Ipsen is voluntarily withdrawing its cancer drug Tazverik (tazemetostat) from the market after an independent data monitoring committee identified cases of secondary cancers originating in blood-forming tissue among patients in a confirmatory clinical trial. The withdrawal marks a significant setback for patients with epithelioid sarcoma and follicular lymphoma who relied on the drug, and raises broader questions about the accelerated approval pathway that brought Tazverik to market.
Tazverik was first approved by the FDA in January 2020 under the accelerated approval program for the treatment of epithelioid sarcoma, a rare soft tissue cancer with few treatment options. The drug later received an additional accelerated approval for relapsed or refractory follicular lymphoma. Under the accelerated approval pathway, drugs can reach patients faster based on surrogate endpoints — such as tumor shrinkage — while the manufacturer conducts confirmatory trials to verify actual clinical benefit.
What the Monitoring Committee Found
The independent data monitoring committee reviewing the confirmatory trial for Tazverik's follicular lymphoma indication reported an unexpected number of cases of secondary hematological malignancies — new cancers arising in the blood and bone marrow — among patients receiving the drug. These secondary cancers, which can include myelodysplastic syndrome and acute myeloid leukemia, are serious and often life-threatening conditions.
The specific mechanism by which Tazverik might promote secondary blood cancers is related to its pharmacological target. Tazverik is an EZH2 inhibitor — it blocks an enzyme called enhancer of zeste homolog 2 that plays a role in gene regulation through epigenetic modification. EZH2 is a histone methyltransferase that adds methyl groups to histones, the proteins around which DNA is wound, effectively silencing certain genes.
In cancers where EZH2 is overactive or mutated, this gene silencing can suppress tumor suppressor genes and promote cancer growth. By blocking EZH2, Tazverik was designed to reactivate these silenced genes and slow cancer progression. However, EZH2 also plays important roles in normal blood cell development, and its inhibition could potentially disrupt the regulation of blood-forming stem cells in ways that predispose to secondary malignancies.
Accelerated Approval Under Scrutiny
Tazverik's withdrawal adds to growing debate about the FDA's accelerated approval pathway. The program was designed to speed access to potentially life-saving treatments for serious conditions, particularly when no adequate alternatives exist. In exchange for earlier market access, manufacturers agree to conduct post-marketing confirmatory studies to verify that the drug provides genuine clinical benefit.
Critics have argued that some drugs approved under this pathway remain on the market for years without confirmatory evidence, and that the safety monitoring during the post-approval period is not always sufficiently rigorous. The FDA has taken steps in recent years to strengthen the accelerated approval program, including more actively pursuing withdrawal of drugs whose confirmatory trials fail.
Tazverik's case is somewhat different — the confirmatory trial did not merely fail to show benefit but actively identified a new safety concern. This outcome underscores the importance of the confirmatory trial requirement and validates the regulatory framework's design, even as it highlights the risks patients face when using drugs approved on the basis of preliminary evidence.
Impact on Patients
For patients currently taking Tazverik, the withdrawal creates an immediate treatment challenge. Epithelioid sarcoma is an extremely rare cancer with very few approved treatment options, and Tazverik was one of the only targeted therapies available. Patients and their oncologists will need to evaluate alternative treatment strategies, which may include conventional chemotherapy, clinical trial enrollment, or off-label use of other targeted agents.
The follicular lymphoma patient population has more treatment alternatives, including several other approved targeted therapies and immunotherapies. However, patients who had responded well to Tazverik and were maintaining disease control will face the disruption of switching treatments, with no guarantee that an alternative will be equally effective.
Broader Implications for EZH2 Inhibitors
The safety signal could have implications beyond Tazverik. Other EZH2 inhibitors are in clinical development, and the finding of secondary hematological malignancies may prompt the FDA to require enhanced safety monitoring for the entire drug class. Manufacturers of competing EZH2 inhibitors will need to evaluate whether the secondary cancer risk is specific to Tazverik or inherent to the mechanism of EZH2 inhibition.
Epigenetic therapies as a class have faced questions about long-term safety, since the enzymes they target are involved in fundamental biological processes that extend well beyond cancer. Disrupting epigenetic regulation can have unpredictable downstream effects on gene expression in healthy tissues, and these effects may take years to manifest as clinical consequences.
Ipsen's Response
Ipsen has stated that it is working with the FDA and international regulatory authorities to manage the withdrawal process, including providing guidance to healthcare providers and patients about transitioning off the drug. The company acquired Tazverik through its purchase of Epizyme in 2022 and had been investing in expanding the drug's approved indications. The withdrawal represents both a financial loss and a strategic setback for Ipsen's oncology portfolio, though the company maintains a diversified pipeline across several therapeutic areas.
This article is based on reporting by endpoints.news. Read the original article.
